A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study

Author

Keywords

*Diabetes Mellitus, Type 2/drug therapy

*Hypoglycemic Agents/therapeutic use/adverse effects

*Glycated Hemoglobin/analysis/drug effects

*Sulfonylurea Compounds/therapeutic use

Dipeptidyl-Peptidase IV Inhibitors/therapeutic use/adverse effects

Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects

Thiazolidinediones/therapeutic use

(227070/Z/23/Z). KGY and TJM were previously supported by Research England's

Expanding Excellence in England (E3) fund. APM declares previous research funding

from Eli Lilly, Pfizer, and AstraZeneca. ERP declares personal fees from

Illumina, Eli Lilly, and Novo Nordisk. RRH is an Emeritus National Institute for

Health and Care Research (NIHR) Senior Investigator, and reports personal fees

from AstraZeneca, Eli Lilly, and Novartis. NS declares personal fees from Abbott

Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi

Pharmaceuticals, Janssen, Menarini-Ricerche, Novartis, Novo Nordisk, Pfizer,

Roche Diagnostics, and Sanofi, and grants to his university from AstraZeneca,

Boehringer Ingelheim, Novartis, and Roche Diagnostics. ATH and BMS are supported

by the NIHR Exeter Clinical Research Facility and AF is supported by the NIHR

Oxford Biomedical Research Centre. AGJ was previously supported by an NIHR

Clinician Scientist Fellowship (CS-2015-15-018) and declares research funding to

his university from the UK Medical Research Council, Diabetes UK, Breakthrough

T1D (formerly JDRF), the European Foundation for the Study of Diabetes, and the

Novo Nordisk Foundation. PC and LMG declare no competing interests.

Representatives from GSK, Takeda, Janssen, Quintiles, AstraZeneca, and Sanofi

attended meetings as part of the industry group involved with the MASTERMIND

Consortium. No industry representatives were involved in the writing of the

manuscript or analysis of data. For all authors, all aforementioned declarations

are outside the submitted work

all authors declare that there are no other

relationships or activities that could appear to have influenced the submitted

Year of Publication

2025

Journal

Lancet

Volume

405

Number of Pages

701-714

ISBN Number

0140-6736

Accession Number

40020703

DOI

10.1016/s0140-6736(24)02617-5